 |
|
Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia
A Randomized, Double-blind, Placebo-Controlled Study
Hsien-Yuan Lane, MD, PhD;
Yue-Cune Chang, PhD;
Yi-Ching Liu, MD;
Chih-Chiang Chiu, MD;
Guochuan E. Tsai, MD, PhD
Arch Gen Psychiatry. 2005;62:1196-1204.
Context Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia.
Objective To determine whether NMDA-glycine site agonists or glycine transporter-1 inhibitors have better efficacy and whether NMDA receptor–enhancing agents have beneficial effects for acute exacerbation of schizophrenia.
Design Randomized, double-blind, placebo-controlled trial.
Setting Inpatient units of 2 major medical centers in Taiwan.
Patients Sixty-five schizophrenic inpatients with acute exacerbation.
Interventions Six weeks of treatment with sarcosine (2 g/d), D-serine (2 g/d), or placebo and concomitant optimal risperidone therapy.
Main Outcome Measures Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) (20 and 17 items) total scores.
Results The sarcosine group revealed more reductions in PANSS total scores than the placebo (P = .04) and D-serine (P<.001) groups. Sarcosine adjunctive treatment was also superior to placebo in reducing SANS-20 (P = .007) and SANS-17 (P = .003) scores and to D-serine in decreasing SANS-20 (P = .006) and SANS-17 (P = .002) scores. The PANSS-general, PANSS-cognitive, and PANSS-depressive symptoms scores and SANS-alogia and SANS–blunted affect scores improved significantly more in sarcosine-cotreated patients than in risperidone monotherapy patients (P .02 for all). Sarcosine adjunctive therapy also surpassed D-serine in terms of PANSS-general, PANSS-positive, PANSS-negative, and PANSS-depressive symptoms scores (P.04 for all). D-Serine and risperidone cotreatment did not differ significantly from risperidone monotherapy in all efficacy domains.
Conclusions This first short-term treatment study on NMDA receptor–enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia. This finding indicates that a glycine transporter 1 inhibitor may be more efficacious than NMDA-glycine site agonists for adjuvant treatment of schizophrenia, at least during the acute phase. Further studies are needed.
Author Affiliations: Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan (Drs Lane and Liu); Institute of Life Sciences and Department of Mathematics, Tamkang University, Taipei, Taiwan (Dr Chang); Department of Psychiatry, Taipei City Psychiatric Center (Dr Chiu); and Laboratory of Molecular and Psychiatric Neuroscience, McLean Hospital and Harvard Medical School, Belmont, Mass (Dr Tsai). Dr Tsai is currently with the Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, Calif.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Disposition of D-Serine in Healthy Adults
Tsai et al.
J Clin Pharmacol 2008;48:524-527.
FULL TEXT
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Buchanan et al.
Schizophr Bull 2007;33:1120-1130.
ABSTRACT
| FULL TEXT
Legal Fallacies of Antipsychotic Drugs
Erickson et al.
J Am Acad Psychiatry Law 2007;35:235-246.
ABSTRACT
| FULL TEXT
Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia.
Heresco-Levy
Evid. Based Ment. Health 2006;9:48-48.
FULL TEXT
|
